- Impact of the updated KLCA-NCC criteria for diagnosis of “probable HCC” in liver MRI: comparisons between KLCA v2022 and v2018
-
Yoon JH
- KMID: 2540825
- J Liver Cancer.
- 2023 Mar;23(1):124-126.
- doi: 10.17998/jlc.2023.3.7
-
- CITED
-
- Close
- SHARE
-
- Close
- How to optimize the treatment strategy for advanced-stage hepatocellular carcinoma with macrovascular invasion
-
Kim BK
- KMID: 2540824
- J Liver Cancer.
- 2023 Mar;23(1):121-123.
- doi: 10.17998/jlc.2023.3.10
-
- CITED
-
- Close
- SHARE
-
- Close
- 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
-
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea
- KMID: 2540823
- J Liver Cancer.
- 2023 Mar;23(1):1-120.
- doi: 10.17998/jlc.2022.11.07
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is... -
- CITED
-
- Close
- SHARE
-
- Close
- Adult hepatoblastoma: making the challenging distinction from hepatocellular carcinoma
-
Pagarigan AKL, Mendoza PGL
- KMID: 2540835
- J Liver Cancer.
- 2023 Mar;23(1):219-224.
- doi: 10.17998/jlc.2023.02.24
Hepatoblastoma is an exceptionally rare malignancy in adults with just over 70 non-pediatric cases reported in literature. Recounted is a case of a 49-year-old female who presented with acute right... -
- CITED
-
- Close
- SHARE
-
- Close
- The development of hepatocellular carcinoma during long-term treatment for recurrent non-small cell lung cancer: a case report
-
Na SK, Kang SH
- KMID: 2540837
- J Liver Cancer.
- 2023 Mar;23(1):230-234.
- doi: 10.17998/jlc.2023.03.03
Multiple primary malignancies (MPMs) are defined as the presence of two or more malignancies in different organs, without a subordinate relationship. Although rarely reported, hepatocellular carcinoma (HCC) occasionally presents with... -
- CITED
-
- Close
- SHARE
-
- Close
- Non-alcoholic fatty liver disease-related hepatocellular carcinoma
-
Daher D, Dahan KSE, Singal AG
- KMID: 2540826
- J Liver Cancer.
- 2023 Mar;23(1):127-142.
- doi: 10.17998/jlc.2022.12.30
Non-alcoholic fatty liver disease (NAFLD), one of the most common causes of liver disease, is an increasingly common cause of hepatocellular carcinoma (HCC). Several demographic, clinical, and genetic factors contribute... -
- CITED
-
- Close
- SHARE
-
- Close
- A case of successful surgical treatment for peritoneal seeding of hepatocellular carcinoma after radiotherapy and atezolizumab plus bevacizumab combination treatment
-
Cho Y, Kim BH, Kim TH, Koh YH, Park JW
- KMID: 2540833
- J Liver Cancer.
- 2023 Mar;23(1):206-212.
- doi: 10.17998/jlc.2023.02.09
Peritoneal seeding of hepatocellular carcinoma (HCC) is incurable and has poor prognosis. A 68-year-old man underwent surgical resection for a 3.5 cm single nodular HCC at the tip of segment... -
- CITED
-
- Close
- SHARE
-
- Close
- Parenchymal-sparing hepatectomy for multiple bilobar colorectal liver metastases in a Jehovah’s witness: a case report
-
Ratnayake S, Subasinghe D, Dassanayake V, Sivaganesh S
- KMID: 2540832
- J Liver Cancer.
- 2023 Mar;23(1):202-205.
- doi: 10.17998/jlc.2023.01.27
Parenchymal-sparing hepatectomy (PSH), though technically challenging, is emerging as a choice of treatment for colorectal liver metastases (CRLM). PSH in Jehovah’s witness (JW) patients, for whom transfusion is not an... -
- CITED
-
- Close
- SHARE
-
- Close
- Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab
-
Kim YT, Kim J, Seong J
- KMID: 2540836
- J Liver Cancer.
- 2023 Mar;23(1):225-229.
- doi: 10.17998/jlc.2023.02.27
Recently, the superiority of atezolizumab plus bevacizumab (AteBeva) over sorafenib was proven in the IMbrave150 trial, and AteBeva became the first-line systemic treatment for untreated, unresectable hepatocellular carcinoma (HCC). While... -
- CITED
-
- Close
- SHARE
-
- Close
- A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
-
Kim HJ, Hwang SY, Im JW, Jeon KJ, Jeon W
- KMID: 2540834
- J Liver Cancer.
- 2023 Mar;23(1):213-218.
- doi: 10.17998/jlc.2023.02.23
Recently, the efficacy of immuno-oncologic agents for advanced hepatocellular carcinoma (HCC) has been proven in several trials. In particular, atezolizumab with bevacizumab (AteBeva), as a first-line therapy for advanced HCC,... -
- CITED
-
- Close
- SHARE
-
- Close
- Radiologic features of hepatocellular carcinoma related to prognosis
-
Hwang SH, Rhee H
- KMID: 2540827
- J Liver Cancer.
- 2023 Mar;23(1):143-156.
- doi: 10.17998/jlc.2023.02.16
The cross-sectional imaging findings play a crucial role in the diagnosis of hepatocellular carcinoma (HCC). Recent studies have shown that imaging findings of HCC are not only relevant for the... -
- CITED
-
- Close
- SHARE
-
- Close
- Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment
-
Jin S, Choi WM, Shim JH, Lee D, Kim KM, Lim YS, Lee HC, Jung J, Yoon SM, Choi J
- KMID: 2540830
- J Liver Cancer.
- 2023 Mar;23(1):177-188.
- doi: 10.17998/jlc.2023.03.04
Background/Aim: The Barcelona Clinic Liver Cancer (BCLC) guidelines recommend systemic therapy as the only first-line treatment for patients with BCLC stage C hepatocellular carcinoma (HCC) despite its heterogeneity of disease... -
- CITED
-
- Close
- SHARE
-
- Close
- Use of doxorubicin-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein invasion: a prospective study
-
Yu SJ, Lee YB, Cho EJ, Lee JH, Kim HC, Chung JW, Yoon JH, Kim YJ
- KMID: 2540829
- J Liver Cancer.
- 2023 Mar;23(1):166-176.
- doi: 10.17998/jlc.2023.02.08
Background/Aim: To evaluate the applicability of transarterial chemoembolization (TACE) treatment with doxorubicin drug-eluting beads (DEBs) in advanced hepatocellular carcinoma (HCC) patients with portal vein invasion (PVI). Methods: This prospective study was... -
- CITED
-
- Close
- SHARE
-
- Close
- Diagnostic performance of the 2022 KLCA-NCC criteria for hepatocellular carcinoma on magnetic resonance imaging with extracellular contrast and hepatobiliary agents: comparison with the 2018 KLCA-NCC criteria
-
Yoon JK, Lee S, Hwang JA, Lee JE, Kim Ss, Kim MJ
- KMID: 2540828
- J Liver Cancer.
- 2023 Mar;23(1):157-165.
- doi: 10.17998/jlc.2023.02.07
Background/Aim: This study aimed to determine the diagnostic performance of 2022 Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) imaging criteria compared with the 2018 KLCA-NCC for hepatocellular carcinoma (HCC) in... -
- CITED
-
- Close
- SHARE
-
- Close
- Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study
-
Yoo SH, Kim SS, Kim SG, Kwon JH, Lee HA, Seo YS, Jung YK, Yim HJ, Song DS, Kang SH, Kim MY, Ahn YH, Han J, Kim YS, Chang Y, Jeong SW, Jang JY, Yoo JJ
- KMID: 2540831
- J Liver Cancer.
- 2023 Mar;23(1):189-201.
- doi: 10.17998/jlc.2023.03.11
Background/Aim: Abdominal ultrasonography (USG) is recommended as a surveillance test for high-risk groups for hepatocellular carcinoma (HCC). This study aimed to analyze the current status of the national cancer surveillance... -
- CITED
-
- Close
- SHARE
-
- Close
